Cumberland Pharmaceuticals Inc. (CPIX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 37 | 36 | 42 | 40 | 38 | 45 | 31 | 38 |
| Operating profit | $m | -3 | -10 | ||||||
| Net profit | $m | -3 | -4 | -6 | -6 | -6 | -3 | -11 | -8 |
| EPS reported | $ | -0.19 | -0.71 | ||||||
| Operating cashflow per share | $ | 0.33 | 0.05 | ||||||
| Capex per share | $ | 0.01 | 0.12 | ||||||
| FCF per share | $ | 0.32 | -0.07 | ||||||
| Free cash flow | $m | 5 | -1 | ||||||
| Net debt | $m | -6 | -4 | ||||||
| Book value equity | $m | 25 | 17 | ||||||
| Book value per share | $ | 1.66 | 1.16 | ||||||
| Number of shares | m | 14.96 | 14.98 | ||||||
| DPS (TTM paid) | $ | 0.00 | 1.50 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.39 | 3.41 | ||||||
| P/S LTM | x | 1.34 | 1.90 | ||||||
| P/FCF LTM | x | 12.31 | -53.58 | ||||||
| EV/EBITDA LTM | x | 19.70 | -10.32 | ||||||
| EV/Sales LTM | x | 1.31 | 3.28 | ||||||
| Earnings Yield LTM | % | -4.76% | -10.43% | ||||||
| FCF Yield | % | +8.12% | -1.87% | ||||||
| Quality | |||||||||
| ROE | % | -11.40% | -47.10% | ||||||
| ROIC | % | -6.89% | -34.15% | ||||||
| Operating margin | % | -6.27% | -30.79% | ||||||
| Gross margin | % | +85.02% | +83.37% | ||||||
| FCF/Sales | % | +10.86% | -3.55% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +17.57% | -17.43% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | +22.09% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.47 | -0.24 | ||||||
| Net Debt/EBITDA | x | -0.43 | -0.15 | ||||||
| EBIT/Net interest | x | -5.63 | -31.13 | ||||||
| Net debt/market cap | % | +8.80% | 0.00% | ||||||
| Net debt/Equity | x | -0.25 | -0.22 | ||||||
| Gross debt/equity | x | 0.41 | 0.27 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cumberland Pharmaceuticals Inc. (CPIX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free